In 72 mice with renal ischemia-reperfusion injury, liraglutide reduced kidney damage by shifting macrophages from inflammatory M1 to protective M2 type via STAT3/6 signaling, which inhibited macrophage extracellular trap formation and prevented ferroptosis — a specific form of iron-dependent cell death.
M1→M2 macrophage shiftLiraglutide switched kidney macrophages from damaging M1 to protective M2 type through STAT3/6 signaling — this shift was essential for preventing kidney injury, as blocking STAT3/6 reversed all protection
What the researchers found
Liraglutide relieved renal ischemia-reperfusion injury and ferroptosis in vivo. It inhibited macrophage extracellular trap (MET) formation both in vivo and in vitro. Liraglutide decreased STAT1 phosphorylation and increased STAT3/6 phosphorylation, promoting M2 macrophage polarization. STAT3/6 inhibition reversed all liraglutide protective effects.
Why it matters
Kidney transplantation and major surgery frequently cause ischemia-reperfusion injury, and there are no approved drugs to prevent it. This study identifies a specific, druggable mechanism by which a widely available GLP-1 drug protects the kidneys — through macrophage polarization and ferroptosis prevention — opening a potential new indication for liraglutide.
The numbers in context
72 mice used, 8 per group. Both in vivo kidney injury model and in vitro co-culture system employed.
How the study worked
Animal study: 72 C57BL/6J mice (8 per group) with surgically induced renal ischemia-reperfusion injury. In vitro co-culture of primary tubular epithelium with RAW264.7 macrophages under hypoxia/reoxygenation. METs measured by extracellular DNA, neutrophil elastase, and myeloperoxidase. F4/80 and citH3 immunofluorescence for MET visualization.
Who was studied
C57BL/6J mice with induced renal ischemia-reperfusion injury
What this study cannot tell us
Mouse model — surgical ischemia in mice doesn't fully replicate human kidney transplantation or acute kidney injury. Liraglutide dosing and timing in the mouse model may not translate directly to clinical use. No long-term kidney function or histology follow-up. RAW264.7 is an immortalized cell line that may not fully represent primary macrophages.
How to read the evidence
Rated preliminary: well-designed mechanistic animal study with 72 mice and both in vivo/in vitro confirmation, but no human clinical data.
When this study was published
Published in 2024. Addresses the active research area of GLP-1 RA organ protection beyond metabolic effects.
The bigger picture
The discovery that GLP-1 drugs can prevent kidney ischemia injury adds to the growing list of organ-protective effects beyond glucose control. This is particularly relevant for transplant medicine, where protecting the donor kidney during the inevitable ischemia period could improve graft survival.
Questions still open
- Could pretreatment with GLP-1 RAs before kidney transplantation reduce ischemia-reperfusion injury in humans?
- Do other GLP-1 RAs (semaglutide, tirzepatide) show similar renoprotective effects through this mechanism?
- Is the ferroptosis-prevention mechanism also responsible for the kidney benefits seen in GLP-1 clinical trials?
Common questions
Can GLP-1 drugs protect the kidneys during surgery or transplantation?
What is ferroptosis and why does it matter for kidneys?
Read the original research
Liraglutide alleviates ferroptosis in renal ischemia reperfusion injury via inhibiting macrophage extracellular trap formation.
International immunopharmacology, 142(Pt B), 113258
Citation
Sun, Zejia; Zhang, Feilong; Gao, Zihao; Wu, Jiyue; Bi, Qing; Zheng, Xiang; Zhang, Jiandong; Cao, Peng; Wang, Wei. (2024). Liraglutide alleviates ferroptosis in renal ischemia reperfusion injury via inhibiting macrophage extracellular trap formation.. International immunopharmacology, 142(Pt B), 113258. https://doi.org/10.1016/j.intimp.2024.113258